Lista de obras - Stephen H Gillespie - Dominio Público Uruguay

A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses

artículo científico publicado en 2017

A comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials for new regimens

artículo científico publicado en 2017

A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis

artículo científico publicado en 2015

A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)

artículo científico publicado en 2016

A practical guide to measuring mutation rates in antibiotic resistance

artículo científico publicado en 2008

A spatially heterogeneous network-based metapopulation software model applied to the simulation of a pulmonary tuberculosis infection

scientific article published on 23 August 2018

An improved method for detection of pyrazinamide resistance in Mycobacterium tuberculosis

artículo científico publicado en 2012

Analysis of rpoB and pncA mutations in the published literature: an insight into the role of oxidative stress in Mycobacterium tuberculosis evolution?

artículo científico publicado en 2005

Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment

artículo científico publicado en 2013

Biomarkers of treatment response in clinical trials of novel antituberculosis agents

artículo científico publicado en 2007

Blood culture bottle culture of pleural fluid in pleural infection

artículo científico publicado en 2011

Can phenotypic data complement our understanding of antimycobacterial effects for drug combinations?

scientific article published on 01 December 2019

Centrifugation and decontamination procedures selectively impair recovery of important populations in Mycobacterium smegmatis

artículo científico publicado en 2018

Chasing Koch's chimera.

artículo científico publicado en 2013

Community-acquired pneumonia and tuberculosis: differential diagnosis and the use of fluoroquinolones

artículo científico

Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.

artículo científico publicado en 2018

Defining dormancy in mycobacterial disease.

artículo científico publicado en 2016

Detecting Phenotypically Resistant Mycobacterium tuberculosis Using Wavelength Modulated Raman Spectroscopy

artículo científico publicado en 2018

Detection and identification of bacteria in clinical samples by 16S rRNA gene sequencing: comparison of two different approaches in clinical practice

artículo científico publicado en 2011

Direct comparison of Xpert MTB/RIF assay with liquid and solid mycobacterial culture for quantification of early bactericidal activity

artículo científico publicado en 2013

Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients

artículo científico publicado en 2015

Effect of cotrimoxazole on causes of death, hospital admissions and antibiotic use in HIV-infected children.

artículo científico publicado en 2007

Effective anti-tuberculosis therapy correlates with plasma small RNA.

artículo científico publicado en 2015

Enhanced Methodologies for Detecting Phenotypic Resistance in Mycobacteria.

artículo científico publicado en 2018

Erratum to: Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials.

artículo científico publicado en 2016

Forecasting Clinical Dose-Response From Preclinical Studies in Tuberculosis Research: Translational Predictions With Rifampicin.

artículo científico publicado en 2018

Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis

artículo científico publicado en 2014

Gender differences in tuberculosis treatment outcomes: a post hoc analysis of the REMoxTB study

scientific article published on 17 October 2018

Genomic Investigations unmask Mycoplasma amphoriforme, a new respiratory pathogen

artículo científico publicado en 2014

Greater Early Bactericidal Activity at Higher Rifampicin Doses Revealed by Modeling and Clinical Trial Simulations

scientific article published on 01 August 2018

Heat-inactivation renders sputum safe and preserves RNA for downstream molecular tests

artículo científico publicado en 2019

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial

artículo científico publicado en 2016

HspX knock-out in Mycobacterium tuberculosis leads to shorter antibiotic treatment and lower relapse rate in a mouse model--a potential novel therapeutic target

artículo científico publicado en 2014

Identification of 2-aminothiazole-4-carboxylate derivatives active against Mycobacterium tuberculosis H37Rv and the beta-ketoacyl-ACP synthase mtFabH

artículo científico publicado en 2009

IkappaB genetic polymorphisms and invasive pneumococcal disease

artículo científico publicado en 2007

Impact of cotrimoxazole on carriage and antibiotic resistance of Streptococcus pneumoniae and Haemophilus influenzae in HIV-infected children in Zambia

artículo científico publicado en 2010

Improved power for TB Phase IIa trials using a model-based pharmacokinetic-pharmacodynamic approach compared with commonly used analysis methods.

artículo científico publicado en 2017

Innovative Trial Designs Are Practical Solutions for Improving the Treatment of Tuberculosis

artículo científico publicado en 2012

Label-free optical vibrational spectroscopy to detect the metabolic state of M. tuberculosis cells at the site of disease.

artículo científico publicado en 2017

Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials

artículo científico publicado en 2016

Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study

artículo científico publicado en 2018

Managing malaria in tuberculosis patients on fluoroquinolone-containing regimens: assessing the risk of QT prolongation.

artículo científico publicado en 2012

Mimicking in-vivo exposures to drug combinations in-vitro: anti-tuberculosis drugs in lung lesions and the hollow fiber model of infection

artículo científico publicado en 2019

Model-Based Relationship between the Molecular Bacterial Load Assay and Time to Positivity in Liquid Culture

scientific article published on 23 September 2019

Modelling the effects of bacterial cell state and spatial location on tuberculosis treatment: Insights from a hybrid multiscale cellular automaton model.

artículo científico publicado en 2018

Molecular Bacterial Load Assay Concurs with Culture on NaOH-Induced Loss of Mycobacterium tuberculosis Viability

artículo científico publicado en 2019

Molecular bacterial load assay, a culture-free biomarker for rapid and accurate quantification of sputum Mycobacterium tuberculosis bacillary load during treatment

artículo científico publicado en 2011

Moxifloxacin for tuberculosis

artículo científico publicado en 2012

Moxifloxacin replacement in contemporary tuberculosis drug regimens is ineffective against persistent Mycobacterium tuberculosis: Novel insights from the Cornell mouse model.

artículo científico publicado en 2018

Mycobacterial Load Assay.

artículo científico publicado en 2017

New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects

artículo científico

OMNIgene.SPUTUM suppresses contaminants while maintaining Mycobacterium tuberculosis viability and obviates cold-chain transport.

artículo científico publicado en 2018

Optimising molecular diagnostic capacity for effective control of tuberculosis in high-burden settings

artículo científico publicado en 2016

PTPN22 and invasive bacterial disease

article

Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis.

artículo científico publicado en 2017

Phenotypic resistance in mycobacteria: is it because I am old or fat that I resist you?

artículo científico publicado en 2015

Pretreatment chest x-ray severity and its relation to bacterial burden in smear positive pulmonary tuberculosis.

artículo científico publicado en 2018

Profiling persistent tubercule bacilli from patient sputa during therapy predicts early drug efficacy

artículo científico publicado en 2016

Pseudomonas aeruginosa intensive care unit outbreak: winnowing of transmissions with molecular and genomic typing

artículo científico publicado en 2017

Routine use of microbial whole genome sequencing in diagnostic and public health microbiology

artículo científico publicado en 2012

Sequetyping: serotyping Streptococcus pneumoniae by a single PCR sequencing strategy

artículo científico publicado en 2012

Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis

artículo científico publicado en 2015

Spot sputum samples are at least as good as early morning samples for identifying Mycobacterium tuberculosis.

artículo científico publicado en 2017

Strategies and Challenges Involved in the Discovery of New Chemical Entities During Early-Stage Tuberculosis Drug Discovery

scientific article published on 22 March 2012

Streptococcus pseudopneumoniae identification by pherotype: a method to assist understanding of a potentially emerging or overlooked pathogen

artículo científico publicado en 2012

The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis.

artículo científico publicado en 2018

The adaptive potential during nasopharyngeal colonisation of Streptococcus pneumoniae ⬇️

artículo científico publicado el 10 de septiembre de 2011

The implications of model-informed drug discovery and development for tuberculosis

artículo científico publicado en 2016

The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations

artículo científico publicado en 2014

The role of moxifloxacin in tuberculosis therapy

artículo científico publicado en 2016

Tools for detection of Mycoplasma amphoriforme: a primary respiratory pathogen?

artículo científico publicado en 2014

Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status

scientific article published on 14 August 2019

Using RT qPCR for Quantifying Mycobacteria marinum from In Vitro and In Vivo Samples

artículo científico publicado en 2018

When is an outbreak not an outbreak? Fit, divergent strains of Mycobacterium tuberculosis display independent evolution of drug resistance in a large London outbreak.

artículo científico publicado en 2012

Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study

artículo científico publicado en 2013

Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?

artículo científico publicado en 2011

XDR-TB, what is it; how is it treated; and why is therapeutic failure so high?

artículo científico publicado en 2011

Lista de obras de Stephen H Gillespie

A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses

A comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials for new regimens

A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis

A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)

A practical guide to measuring mutation rates in antibiotic resistance

A spatially heterogeneous network-based metapopulation software model applied to the simulation of a pulmonary tuberculosis infection

An improved method for detection of pyrazinamide resistance in Mycobacterium tuberculosis

Analysis of rpoB and pncA mutations in the published literature: an insight into the role of oxidative stress in Mycobacterium tuberculosis evolution?

Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment

Biomarkers of treatment response in clinical trials of novel antituberculosis agents

Blood culture bottle culture of pleural fluid in pleural infection

Can phenotypic data complement our understanding of antimycobacterial effects for drug combinations?

Centrifugation and decontamination procedures selectively impair recovery of important populations in Mycobacterium smegmatis

Chasing Koch's chimera.

Community-acquired pneumonia and tuberculosis: differential diagnosis and the use of fluoroquinolones

Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.

Defining dormancy in mycobacterial disease.

Detecting Phenotypically Resistant Mycobacterium tuberculosis Using Wavelength Modulated Raman Spectroscopy

Detection and identification of bacteria in clinical samples by 16S rRNA gene sequencing: comparison of two different approaches in clinical practice

Direct comparison of Xpert MTB/RIF assay with liquid and solid mycobacterial culture for quantification of early bactericidal activity

Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients

Effect of cotrimoxazole on causes of death, hospital admissions and antibiotic use in HIV-infected children.

Effective anti-tuberculosis therapy correlates with plasma small RNA.

Enhanced Methodologies for Detecting Phenotypic Resistance in Mycobacteria.

Erratum to: Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials.

Forecasting Clinical Dose-Response From Preclinical Studies in Tuberculosis Research: Translational Predictions With Rifampicin.

Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis

Gender differences in tuberculosis treatment outcomes: a post hoc analysis of the REMoxTB study

Genomic Investigations unmask Mycoplasma amphoriforme, a new respiratory pathogen

Greater Early Bactericidal Activity at Higher Rifampicin Doses Revealed by Modeling and Clinical Trial Simulations

Heat-inactivation renders sputum safe and preserves RNA for downstream molecular tests

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial

HspX knock-out in Mycobacterium tuberculosis leads to shorter antibiotic treatment and lower relapse rate in a mouse model--a potential novel therapeutic target

Identification of 2-aminothiazole-4-carboxylate derivatives active against Mycobacterium tuberculosis H37Rv and the beta-ketoacyl-ACP synthase mtFabH

IkappaB genetic polymorphisms and invasive pneumococcal disease

Impact of cotrimoxazole on carriage and antibiotic resistance of Streptococcus pneumoniae and Haemophilus influenzae in HIV-infected children in Zambia

Improved power for TB Phase IIa trials using a model-based pharmacokinetic-pharmacodynamic approach compared with commonly used analysis methods.

Innovative Trial Designs Are Practical Solutions for Improving the Treatment of Tuberculosis

Label-free optical vibrational spectroscopy to detect the metabolic state of M. tuberculosis cells at the site of disease.

Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials

Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study

Managing malaria in tuberculosis patients on fluoroquinolone-containing regimens: assessing the risk of QT prolongation.

Mimicking in-vivo exposures to drug combinations in-vitro: anti-tuberculosis drugs in lung lesions and the hollow fiber model of infection

Model-Based Relationship between the Molecular Bacterial Load Assay and Time to Positivity in Liquid Culture

Modelling the effects of bacterial cell state and spatial location on tuberculosis treatment: Insights from a hybrid multiscale cellular automaton model.

Molecular Bacterial Load Assay Concurs with Culture on NaOH-Induced Loss of Mycobacterium tuberculosis Viability

Molecular bacterial load assay, a culture-free biomarker for rapid and accurate quantification of sputum Mycobacterium tuberculosis bacillary load during treatment

Moxifloxacin for tuberculosis

Moxifloxacin replacement in contemporary tuberculosis drug regimens is ineffective against persistent Mycobacterium tuberculosis: Novel insights from the Cornell mouse model.

Mycobacterial Load Assay.

New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects

OMNIgene.SPUTUM suppresses contaminants while maintaining Mycobacterium tuberculosis viability and obviates cold-chain transport.

Optimising molecular diagnostic capacity for effective control of tuberculosis in high-burden settings

PTPN22 and invasive bacterial disease

Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis.

Phenotypic resistance in mycobacteria: is it because I am old or fat that I resist you?

Pretreatment chest x-ray severity and its relation to bacterial burden in smear positive pulmonary tuberculosis.

Profiling persistent tubercule bacilli from patient sputa during therapy predicts early drug efficacy

Pseudomonas aeruginosa intensive care unit outbreak: winnowing of transmissions with molecular and genomic typing

Routine use of microbial whole genome sequencing in diagnostic and public health microbiology

Sequetyping: serotyping Streptococcus pneumoniae by a single PCR sequencing strategy

Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis

Spot sputum samples are at least as good as early morning samples for identifying Mycobacterium tuberculosis.

Strategies and Challenges Involved in the Discovery of New Chemical Entities During Early-Stage Tuberculosis Drug Discovery

Streptococcus pseudopneumoniae identification by pherotype: a method to assist understanding of a potentially emerging or overlooked pathogen

The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis.

The adaptive potential during nasopharyngeal colonisation of Streptococcus pneumoniae ⬇️

The implications of model-informed drug discovery and development for tuberculosis

The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations

The role of moxifloxacin in tuberculosis therapy

Tools for detection of Mycoplasma amphoriforme: a primary respiratory pathogen?

Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status

Using RT qPCR for Quantifying Mycobacteria marinum from In Vitro and In Vivo Samples

When is an outbreak not an outbreak? Fit, divergent strains of Mycobacterium tuberculosis display independent evolution of drug resistance in a large London outbreak.

Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study

Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?

XDR-TB, what is it; how is it treated; and why is therapeutic failure so high?